Biotechnology company Rinri Therapeutics stated on Friday that it has raised GBP1.4m in seed funding co-led by Boehringer Ingelheim Venture Fund and UCB Ventures and joined by BioCity/
The funds will be used to support Rinri's ongoing growth including advancing its novel regenerative cell therapy to treat Sensorineural Hearing Loss through the repair of the damaged cytoarchitecture in the inner ear. SNHL happens when there is damage to the hair cells in the cochlear and/or the auditory nerve.
Under the terms of the financing agreement, Detlev Mennerich, PhD, investment director at Boehringer Ingelheim Venture Fund; Erica Whittaker, PhD, head of UCB Ventures; and Claire Brown, PhD, investment director at BioCity have been elected to Rinri's board of directors.
Concurrently, Rinri has named Simon Chandler PhD as its new CEO. Most recently, Dr Chandler has spent the past four years at IP Group, where he was responsible for early stage investments and company-building for UK university life science spinouts.
(USD1=GBP0.785710)
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business